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Several groups have modified adenoviral vector broad tropism and have achieved a targeted gene expression in somatic tissues using a variety of approaches including modification of viral structural proteins and inclusion of tissue-specific promoters. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, the finding that the adenoviral background can cause either loss of tissue specificity [10] [11] [12] or down-regulation of promoters used to drive transgene expression 12 has limited the application of the last approach.
Transcriptional interference mediated by several ciselements, mainly located on the left end of the adenovirus chromosome, appears to be accountable for this phenomenon ( Figure 1a ). The inverted terminal repeat (ITR) contains redundant binding sites for cellular factors and stimulates transcription from E1 and E4 genes. [13] [14] [15] The bipartite E1A enhancer trans-activates the E1A gene through the cellular protein EF-1A and controls the expression of the early genes after infection. 16, 17 The promoter for the intermediate transcript pIX is situated just downstream of the canonical E1 cloning site for expression cassettes. Since some of these elements overlap with the viral origin of replication and the packaging signal, they cannot be deleted or inactivated. Thus other strategies based on the use of transcription modulators have been developed to achieve targeted gene delivery. Restoration of promoter selectivity in cell culture was successfully obtained by flanking an expression cassette that contained a fragment of the promoter of the ERBB2 gene and the herpes simplex thymidine kinase gene, with the bovine growth hormone transcription terminator. 18 Furthermore, the appropriate activity of a metalinducible promoter was re-established when transcriptional insulator elements derived from the chicken ␥-globin locus (HS-4), were employed. 19 We attempted to achieve cardiac specific gene expression by cloning the rat ␣-myosin heavy chain promoter (␣MyHC) in a recombinant adenovirus. To maximize cloning capacity, we have employed a short version of the ␣MyHC promoter (Ϫ613 to +32) that is sufficient for directing high levels of cardiac-specific gene expression in transgenic mice, 20, 21 as well as after direct gene injection. 22 However, when a recombinant adenovirus carrying the ␣MyHC promoter driving the chloramphenicol report gene (CAT) was tested in vivo by direct injection, we found that CAT expression was not restricted to the heart, but was also detectable in several tissues (data not shown). Moreover, a comparison between plasmid and viral constructs (with the CMV promoter used as a reference) revealed that the activity of the ␣MyHC promoter in heart was also severely depressed by the adenovirus DNA context (data not shown).
Since a transcriptional terminator can both reinstate restricted gene expression 18 and reduce the inhibitory transcriptional interference between contiguous promoters, 23 we have cloned the human growth hormone terminator upstream of the ␣MyHC promoter. Experi- 27 ments presented in the current work have tested the ability of this terminator to shield heterologous transcription units in vivo.
Different recombinant adenoviruses were assembled by homologous recombination in 293 cells (Figure 1b) . The constructs carrying a promoterless CAT gene (AdCAT) and its derivative (Ad ter CAT) containing the human growth hormone terminator, were tested in vivo to determine levels of nonspecific CAT reporter gene expression and terminator activity. The construct AdPCMVCAT, expressing CAT under the cytomegalovirus promoter, was used as a positive standard control. Plaque forming units (1-2 × 10 8 ) of recombinant viruses were injected into the heart and skeletal muscle (tibialis anterior) of CD-1 mice, and CAT activity was determined 1 week later. As shown in Figure 2 , the AdCAT construct, lacking an exogenous promoter, was active in both tissues with high levels of CAT activity detected in skeletal muscle. Remarkably, in this tissue AdCAT was just two-fold less active than AdPCMVCAT that carries the CMV promoter.
RNase protection was next employed to map the transcription start site(s) driving CAT expression. When a riboprobe containing the first 40 nucleotides of the CAT gene preceded by 218 nucleotides of upstream adenovirus sequence was hybridized to 10 g of total RNA purified from AdCAT infected rat fetal cardiomyocytes, a 135 nucleotide-protected fragment was detected ( Figure  3) . Thus, in the absence of any heterologous promoter, transcription seems to initiate within the adenovirus E1 enhancer region, 261 nucleotides from the beginning of the ITR, 95 nucleotides upstream of the CAT reporter gene (Figure 3c ).
Two populations of transcripts initiating at nucleotides 85-95 and nucleotides 148-158 were also mapped in a previous study carried out in a HeLa cell transcription extract using a linearized plasmid containing the left terminal 1339 nucleotides of the AD5 genome. 13 However, it remains to be determined if the start site(s) choice is modulated by different tissue-specific factors or the discrepancy observed between the in vivo and in vitro assays reflects the limitation of the last approach.
When the activity of the recombinant adenovirus Ad ter- CAT was measured, we found that in the presence of the human growth hormone terminator, CAT expression was reduced to background levels in both skeletal muscle and heart (Figure 2 ). To demonstrate that transcriptional shielding was not obtained by simply changing the distance between the CAT gene and the left terminus, we tested a construct carrying the terminator cloned in the reverse orientation. The result of this analysis confirmed that only the presence of the terminator in its physiological 5'→3' orientation abolishes cryptic CAT activation (data not shown).
Figure 3 Mapping of a cryptic transcription initiation site at the left terminus of AdCAT by RNase protection assay. (a) The position and the length of the riboprobe employed is schematically depicted. (b) Reactions were resolved on a 8 M urea-6% polyacrylamide gel and protected fragments visualized by autoradiography. Lanes 1-3 represent the undigested probe, the probe hybridized with total RNA purified from mock-infected rat cardiomyocytes, and the probe hybridized with total RNA purified from AdCAT-infected cardiomyocytes. A and T lanes correspond to sequencing ladders used as size markers. (c) The first 370 nucleotides of the left terminus of the adenovirus are shown with the white and gray boxes defining the ITR and the
These data support the current view that elements present in the backbone of recombinant adenoviruses can promote the assembly of active transcription complexes upstream of the E1 region. Furthermore, they show that one copy of the human growth hormone terminator has the ability to completely silence viral transcriptional interference mediated by viral elements located both upstream and downstream of the E1A region. Thus the use of two terminators flanking the expression cassette does not appear to be necessary.
Since our main aim was to test whether the terminator can restore cardiac specificity to the ␣MyHC promoter in Gene Therapy vivo, we injected the recombinant viruses AdP␣CAT and Ad ter P␣CAT into the heart and skeletal muscle of CD-1 mice. As shown in Figure 4 , after injection into the heart, AdP␣CAT was only approximately 3.5-fold more active than the promoterless construct AdCAT (Figure 2 ) and approximately 100-fold less active than AdPCMVCAT construct (as previously discussed, the activity of the ␣MyHC promoter appears to be negatively regulated by the adenovirus context as reported also for another muscle promoter, the ventricular/slow muscle myosin light chain 1 promoter 12 ). CAT activity was still detectable in skeletal muscle, although it was approximately nine-fold less than in the heart. This result clearly indicates loss of selective ␣MyHC activation, since direct injection in skeletal muscle of a plasmid carrying the same transcription cassette without adenoviral sequences did not result in any appreciable reporter gene expression. 22 Unexpectedly, the presence of the terminator element did not improve either the ␣MyHC level of expression in the heart or repress viral interference in skeletal muscle. Paradoxically in the latter tissue, CAT activity increased almost four-fold when the terminator was present (Figure 4) . The data presented in this study demonstrate that the ability of transcription terminator elements to re-establish selective expression in adenoviral vectors is subject to important functional limitations and consequently caution should be taken when this approach is pursued.
Our results also show that the first 200-250 nucleotides of the left terminus of the adenovirus contain enough information to direct the assembly of active transcription complexes and more importantly, to initiate ectopic transcription within the E1A packaging signal (Figure 3) . Thus, loss of tissue-specific expression for transgenes cloned in the rightward-orientation could occur by a passive 'readthrough' of the heterologous promoter, rather than by an active and direct activation of it from 5' viral enhancers. It should be interesting to study if the activity of leftward-oriented expression cassettes could be improved by a terminator element. By inhibiting the transcription through the cassette, the terminator could both reduce the potential interference occurring between transcription complexes moving toward each other and the synthesis of antisense RNA.
Passive readthrough could also explain why heterologous promoters are often subjected to a negative regulation when cloned in the adenovirus background. In fact, as previously demonstrated for tandemly linked ␣-globin genes, transcriptional interference often results in a substantial inhibition of the downstream promoter. 23 Essentially, activity of the 5' gene indirectly and inversely regulates the activity of the 3' gene. High level of transcription of the first gene generally results in high negative interference of the second one. Although a terminator element placed between the two genes can reduce transcriptional interference, 23 it could also increase transcription of the downstream gene by increasing the local concentration of DNA polymerase 30 ( Figure 5 ). Therefore, cloning a terminator upstream of an expression cassette could inadvertently create a physical arrangement similar to the one observed for Pol I genes, whose promoter activity is enhanced through a cooperative action between transcriptional termination and initiation. The fact that in skeletal muscle the high activity of the cryptic promoter (AdCAT construct) correlates with Ad ter P␣CAT activation ( Table 1 ) provides evidence that the balance between termination/activation and termination could be regulated by the degree of viral ectopic transcription. Consistent with this view is the observation that in heart, where the activity of viral ectopic promoter is low, we did not observe any stimulation of the ␣MyHC promoter (Table 1) . Similarly, the successful use of the terminator to insulate a conditionally expressed transgene driven by the ERBB2 promoter 18 could reflect low levels of viral ectopic transcription in the cell lines tested. However, the possibility that some heterologous promoters could be more susceptible than others to terminator/activation remains to be investigated. In fact, it is possible that our findings could reflect a peculiar interplay between the terminator, the viral ectopic promoter and the ␣MyHC promoter.
Since the data presented in this study indicate that different variables can limit the use of terminator elements a careful functional analysis on transgene expression has to be carried out when this approach is undertaken.
